drugset / Trial / NCT01952249
A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a Phase 1b/2 study of paclitaxel plus demcizumab in subjects with platinum resistant ovarian, primary peritoneal or fallopian tube cancer.
Timeline
- Start
- 2013-08-05
- Primary completion
- 2016-05-10
- Completion
- 2016-07-12
Outcome
Outcome not reported
Stopped: “Phase 2 portion not initiated, no longer pursuing ovarian cancer indication”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Demcizumab | Monoclonal antibody | — | Intravenous |
| Background | Paclitaxel | Small molecule | — | Intravenous |